Search

Your search keyword '"Russo, Letteria"' showing total 13 results
Start Over Author "Russo, Letteria"
13 results on '"Russo, Letteria"'

1. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience

Author

Loteta, Barbara, Paviglianiti, Annalisa, Naso, Virginia, Ferreri, Anna, Moscato, Tiziana, Console, Giuseppe, Canale, Filippo Antonio, Irrera, Giuseppe, Pugliese, Marta, Di Costanzo, Antonella, Provenzano, Pasquale Fabio, Loddo, Viviana, Porto, Gaetana, Cusumano, Giuseppa, Russo, Letteria, Meliambro, Nicola, Romeo, Valentina, Porcino, Domenico, Gallo, Salvatore, Gangemi, Tiziana, Rossetti, Antonio Maria, and Martino, Massimo

Published
2022
Full Text
View/download PDF

3. The impact of education on patients' psycho-emotional status during allogeneic hematopoietic stem cell transplantation: a multicenter prospective study by thes Gruppo Italiano Trapianto di Midollo Osseo.

Author

Cioce, Marco, Borrelli, Ivan, Cappucciati, Lorella, Giori, Manuela, Gobbi, Giorgia, Lucifora, Roberto, Mabilia, Patrizia, Marsullo, Mauro, Prendin, Chiara, Russo, Letteria, Zucca, Maria Silvia, Zega, Maurizio, Sica, Simona, Bacigalupo, Andrea, De Stefano, Valerio, Savoia, Vezio, Celli, Danilo, Garau, Paola, Serra, Nicola, and Botti, Stefano

Subjects
CANCER patient psychology, RESEARCH, INTERVIEWING, COMPARATIVE studies, DESCRIPTIVE statistics, QUESTIONNAIRES, MENTAL depression, HEMATOPOIETIC stem cell transplantation, EMOTIONS, PATIENT education, PSYCHOLOGICAL distress, EDUCATIONAL outcomes, LONGITUDINAL method
Abstract

Depressive disorders are the most common manifestation of psychological distress in allogenic hematopoietic stem cell transplantation. Few studies have yet investigated the relationship between therapeutic educational interventions and outcomes in these patients with specific attention to those related to mental health. Aim of this study was to understand how much educational intervention can represent a protective factor in preventing psycho-emotional distress-related issues in this setting. A prospective observational study of a multicenter cohort was conducted. Adult patients undergoing allogeneic hematopoietic stem cell transplantation. A pre-transplant therapeutic educational programme was offered to a cohort of adult patients undergoing allo-HSCT recruited in ten transplant centers of the GITMO network between May 2018 and January 2019. Depression, Anxiety and Stress scale was used to collect data on psycho-emotional distress at admission (T0), at the day of transplant (T1) and at discharge (T2). Descriptive data were collected and reported, and comparative analyses were done among patients who were compliant with the pre-transplant educational intervention and those who did not (for any reason). A cohort of 133 allo-HSCT patients was observed. In patients who did not receive pre-transplant educational intervention, higher levels of depression at admission (p = 0.01) and at the day of transplant (p = 0.03), higher levels of anxiety (p = 0.01 and p = 0.01 respectively) as well as higher levels of stress (p < 0.01 and p = 0.01) were observed. Problem solving and "face to face" interview were the best methods to provide education to patients. Those who received pre-transplant education through "face-to-face" interview reported significant low levels of depression during the whole hospital stay period (p < 0.01; p = 0.01; p = 0.01) and less anxiety and stress at admission (p < 0.05 and p = 0.01 respectively). Depression was more represented in female than male participants at T0 (16.5% vs 9.0%; p = 0.01), while among T0 and T2 the males had a significant higher increasing of depression than females (p = 0.03). Our study demonstrated that pretreatment therapeutic educational programs with specific learning modalities can be effective in limiting the potential risk of developing moderate-to-severe anxiety-depressive states and stress symptoms related to allo-HSCT. Further studies are needed to confirm our results and to understand whether containing psycho-emotional distress can have any relationship with medium- and long-term post-transplant complications. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

4. Identifying and Managing CAR T-Cell–Mediated Toxicities: on behalf of an Italian CAR-T Multidisciplinary Team

Author

Martino, Massimo, primary, Macheda, Sebastiano, additional, Aguglia, Umberto, additional, Arcudi, Luciano, additional, Pucci, Giulia, additional, Martino, Bruno, additional, Altomonte, Maria, additional, Rossetti, Antonio Maria, additional, Cusumano, Giuseppa, additional, Russo, Letteria, additional, Imbalzano, Lucrezia, additional, Stelitano, Caterina, additional, Alati, Caterina, additional, Germano’, Jessyca, additional, Labate, Demetrio, additional, Amalfi, Vincenzo, additional, Florenzano, Maria Teresa, additional, Morabito, Antonella, additional, Borzumati, Vittoria, additional, Dattola, Vincenzo, additional, Gattuso, Caterina, additional, Moschella, Antonio, additional, Quattrone, Domenico, additional, Curmaci, Francesco, additional, Franzutti, Claudio, additional, Scappatura, Giuseppe, additional, Rao, Carmelo Massimiliano, additional, Loddo, Viviana, additional, Pontari, Antonella, additional, Pellicano’, Maria, additional, Surace, Rosangela, additional, Sanguedolce, Cristina, additional, Naso, Virginia, additional, Ferreri, Anna, additional, Irrera, Giuseppe, additional, Console, Giuseppe, additional, Moscato, Tiziana, additional, Loteta, Barbara, additional, Canale, Filippo Antonio, additional, Trimarchi, Alfonso, additional, Monteleone, Renza, additional, Said, Al Sayyad, additional, Cirrone, Frank, additional, and Bruno, Benedetto, additional

Published
2021
Full Text
View/download PDF

5. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience

Author

Loteta, Barbara, primary, Paviglianiti, Annalisa, additional, Naso, Virginia, additional, Ferreri, Anna, additional, Moscato, Tiziana, additional, Console, Giuseppe, additional, Canale, Filippo Antonio, additional, Irrera, Giuseppe, additional, Pugliese, Marta, additional, Di Costanzo, Antonella, additional, Provenzano, Pasquale Fabio, additional, Loddo, Viviana, additional, Porto, Gaetana, additional, Cusumano, Giuseppa, additional, Russo, Letteria, additional, Meliambro, Nicola, additional, Romeo, Valentina, additional, Porcino, Domenico, additional, Gallo, Salvatore, additional, Gangemi, Tiziana, additional, Rossetti, Antonio Maria, additional, and Martino, Massimo, additional

Published
2021
Full Text
View/download PDF

6. The Burden in Caregivers of Multiple Myeloma Patients Undergoing Outpatient Autologous Stem-Cell Transplantation Compared to Inpatient Transplantation

Author

Martino, Massimo, primary, Pitino, Annalisa, additional, Tripepi, Giovanni, additional, Paviglianiti, Annalisa, additional, Russo, Letteria, additional, Cusumano, Giuseppa, additional, Rossetti, Antonio, additional, Provenzano, Pasquale Fabio, additional, Porto, Gaetana, additional, Meliambro, Nicola, additional, Gallo, Salvatore, additional, Porcino, Domenico, additional, Romeo, Valentina, additional, Gangemi, Tiziana, additional, D’Arrigo, Graziella, additional, Imbalzano, Lucrezia, additional, Console, Giuseppe, additional, and Gori, Mercedes, additional

Published
2021
Full Text
View/download PDF

8. A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model

Author

Martino, Massimo, Ciavarella, Sabino, De Summa, Simona, Russo, Letteria, Meliambro, Nicola, Imbalzano, Lucrezia, Gallo, Giuseppe Alberto, Moscato, Tiziana, Messina, Giuseppe, Ferreri, Anna, Cuzzola, Maria, Irrera, Giuseppe, Naso, Virginia, Cimminiello, Michele, Console, Giuseppe, Loseto, Giacomo, Tommasi, Stefania, and Guarini, Attilio

Published
2018
Full Text
View/download PDF

9. Identifying and managing CAR T-cell–mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team

Author

Martino, Massimo, Macheda, Sebastiano, Aguglia, Umberto, Arcudi, Luciano, Pucci, Giulia, Martino, Bruno, Altomonte, Maria, Rossetti, Antonio Maria, Cusumano, Giuseppa, Russo, Letteria, Imbalzano, Lucrezia, Stelitano, Caterina, Alati, Caterina, Germano’, Jessyca, Labate, Demetrio, Amalfi, Vincenzo, Florenzano, Maria Teresa, Morabito, Antonella, Borzumati, Vittoria, Dattola, Vincenzo, Gattuso, Caterina, Moschella, Antonio, Quattrone, Domenico, Curmaci, Francesco, Franzutti, Claudio, Scappatura, Giuseppe, Rao, Carmelo Massimiliano, Loddo, Viviana, Pontari, Antonella, Pellicano’, Maria, Surace, Rosangela, Sanguedolce, Cristina, Naso, Virginia, Ferreri, Anna, Irrera, Giuseppe, Console, Giuseppe, Moscato, Tiziana, Loteta, Barbara, Canale, Filippo Antonio, Trimarchi, Alfonso, Monteleone, Renza, Al Sayyad, Said, Cirrone, Frank, and Bruno, Benedetto

Abstract

ABSTRACTIntroductionChimeric antigen receptor (CAR)-T-cell therapy is a new treatment for patients with hematologic malignancies in which other therapies have failed.Areas coveredThe review provides an overview for recognizing and managing the most acute toxicities related to CAR-T cells.Expert opinionThe development of immune-mediated toxicities is a common challenge of CAR-T therapy. The mechanism that determines this toxicity is still unclear, although an unfavorable tumor microenvironment and a pro-inflammatory state put patients at risk. The monitoring, diagnosis, and treatment of post-CAR-T toxicities must be determined and based on international guidelines and internal clinical practice. It is urgent to identify biomarkers that can identify patients at greater risk of developing complications. The adoption of consistent grading criteria is necessary to improve toxicity management strategies continually. The first-line therapy consists of supportive care and treatment with tocilizumab or corticosteroids. An early start of cytokine blockade therapies could mitigate toxicity. The plan will include cytokine release prophylaxis, a risk-adapted treatment, prevention of on-target/off-tumor effect, and a switch on/off CAR-T approach.

Published
2022
Full Text
View/download PDF

10. A home-care, early discharge model after autografting in multiple myeloma: results of a three-arm prospective, non-randomized study

Author

Martino, Massimo, primary, Russo, Letteria, additional, Martinello, Tiziana, additional, Gallo, Giuseppe Alberto, additional, Fedele, Roberta, additional, Moscato, Tiziana, additional, Console, Giuseppe, additional, Vincelli, Donatella Iolanda, additional, Ronco, Francesca, additional, Postorino, Maurizio, additional, Irrera, Giuseppe, additional, and Messina, Giuseppe, additional

Published
2014
Full Text
View/download PDF

12. At-Home Management of Aplastic Phase Following High-Dose Melphalan and Autologous Haematopoietic Stem Cell Transplantation for Multiple Myeloma Patients: A Pilot Study

Author

Martino, Massimo, primary, Pellicano’, Grazia, additional, Moscato, Tiziana, additional, Massara, Elisabetta, additional, Fedele, Roberta, additional, Console, Giuseppe, additional, Russo, Letteria, additional, Messina, Giuseppe, additional, Di Filippo Scali, Rosalba, additional, and Irrera, Giuseppe, additional

Published
2011
Full Text
View/download PDF

13. A home-care, early discharge model after autografting in multiple myeloma: results of a three-arm prospective, non-randomized study.

Author

Martino, Massimo, Russo, Letteria, Martinello, Tiziana, Gallo, Giuseppe Alberto, Fedele, Roberta, Moscato, Tiziana, Console, Giuseppe, Vincelli, Donatella Iolanda, Ronco, Francesca, Postorino, Maurizio, Irrera, Giuseppe, and Messina, Giuseppe

Subjects
*MULTIPLE myeloma treatment, *MELPHALAN, *HEMATOPOIETIC agents
Abstract

A letter to the editor is presented which discusses a three-arm prospective and non-randomized study of clinical efficiency of an early discharge model (EDM) and home-care (HC) treatment for multiple myeloma (MM) being treated with high dose melphalan (HDM) with hematopoietic progenitor cell (HPC).

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results